Alemtuzumab: Long term follow-up in a single centre cohort

Willis, Mark, Harding, Katharine, Wardle, Mark, Pickersgill, Trevor, Tomassini, Valentina ORCID: https://orcid.org/0000-0002-7368-6280 and Robertson, Neil ORCID: https://orcid.org/0000-0002-5409-4909 2014. Alemtuzumab: Long term follow-up in a single centre cohort. Journal of Neurology, Neurosurgery & Psychiatry 85 (10) , A1-A57. 10.1136/jnnp-2014-309236.8

Full text not available from this repository.

Abstract

Introduction Alemtuzumab is an anti-CD52 monoclonal antibody, approved for the treatment of relapsing multiple sclerosis (RMS). However, it has significant side effects and long-term follow-up is required to provide accurate information for patient management and counselling. Methods Patients were followed prospectively within an active surveillance program and standardised data collected on a regional database. Data on patient demographics, adverse events, disability trajectories (EDSS), relapses and retreatment intervals were analysed. Results 96 patients with highly active RMS were identified (69F:27M). Mean follow-up post treatment was 5.1 years. Most patients received 2 annual cycles but 27 (28.1%) received 3, 7(7.3%) received 4 and 2 (2.1%) received 5. Pre-and post-treatment annualised relapse rates were 2.1 and 0.4 respectively. Mean change in EDSS from baseline was 0.44. 8 patients developed secondary progression a mean of 2.8 years post treatment. A range of autoimmune disorders (AID), notably thyroid disease was identified in 45 (47%). Discussion Our data supports the effectiveness of alemtuzumab in patients with RMS in reducing relapse rates. However, despite a paucity of inflammatory disease activity, disability accumulation continued in some patients. Overall retreatment rate was 37.5% and AID, whilst common, could be effectively identified through routine surveillance processes and managed without serious consequence.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Medicine
Subjects:	R Medicine > RM Therapeutics. Pharmacology
Publisher:	BMJ Publishing Group
ISSN:	0022-3050
Last Modified:	05 Aug 2023 01:59
URI:	https://orca.cardiff.ac.uk/id/eprint/89241

Citation Data

Actions (repository staff only)

Edit Item